Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Recruiting now NCT02071134
Run by Boston Scientific Corporation · for 18 and older · All sexes
What this study is about
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated. Additionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.
Who can join (things the study team will check)
✅ You may be able to join if…
- Meets criteria established in locally applicable Vercise System Direction for Use
- At least 18 years old
🚫 You may not be able to join if…
- Meets any contraindication in the Vercise System locally applicable Directions for Use Subjects with significant cognitive or psychiatric impairment may be excluded in the evaluation of GXT.
Where this trial is running
- Neurology and Pain Specialty, Aliso Viejo, California, United States
- Cedars Sinai Medical Center, Los Angeles, California, United States
- University of Colorado, Aurora, Colorado, United States
- St. Mary's Hospital and Medical Center, Grand Junction, Colorado, United States
- University of Florida Shands Hospital, Gainesville, Florida, United States
- Mayo Clinic, Jacksonville, Jacksonville, Florida, United States
- University of Miami Hospital, Miami, Florida, United States
- Tallahassee Neurological Clinic, PA, Tallahassee, Florida, United States
- University of South Florida, Tampa, Florida, United States
- St. Luke Regional Medical Center, Boise, Idaho, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Methodist Hospital of Indianapolis, Indianapolis, Indiana, United States
+ 73 more sites.
Who to contact
Heleen Scholtes · 855-213-9890 · BSNClinicalTrials@bsci.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT02071134.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.